SAN DIEGO, June 1, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the Company will present at the Jefferies 2012 Global Healthcare Conference on Wednesday, June 6 at 9:00 a.m. Eastern Time in New York, NY.
(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)
A live audio webcast of the presentation will be accessible on the Investors page of the Company’s website at www.optimerpharma.com. Replays of the presentation will be available at the same location for 90 days following the presentation.
About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a global biopharmaceutical company focused on developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer developed and commercialized DIFICID® (fidaxomicin) tablets, an FDA-approved antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). Optimer has also received marketing authorization for fidaxomicin tablets in the European Union under the trade name DIFICLIR. The company is seeking marketing authorization for fidaxomicin in Canada and is exploring marketing authorization in other parts of the world where C. difficile has emerged as a serious health problem, including Asia. Additional information can be found at http://www.optimerpharma.com.
Contacts
Optimer Pharmaceuticals, Inc.
David Walsey, VP of Investor Relations and Corporate Communications
(858) 964-3418
Canale Communications
Jason I. Spark, Senior Vice President
619-849-6005
Jason@canalecomm.com
SOURCE Optimer Pharmaceuticals, Inc.
